STAT

FEBRUARY 8, 2024

People receiving a double dose of naloxone are no more likely to survive an opioid overdose than people receiving a standard, 4-milligram nasal spray, according to a new study. The new paper , published Thursday in the Centers for Disease Control and Prevention’s Morbidity and Mortality Weekly Report, showed no significant difference in survival rates between people who were revived using 4- and 8-milligram sprays of naloxone, commonly known by the brand name Narcan.

345

345

PharmaVoice

FEBRUARY 8, 2024

While Novo Nordisk and Eli Lilly have a sizable lead in the quickly expanding GLP-1 market, Big Pharma peers are looking for a way in.

130

130

STAT

FEBRUARY 8, 2024

Despite widespread promises of reform after the murder of George Floyd in 2020, in 2023, police killed at least 1,246 people — the most in more than a decade. This police violence is intertwined with a parallel public policy disaster: America’s abysmal mental health systems that force police officers to function as de facto mental health workers.

339

339

The Pharmacist

FEBRUARY 8, 2024

Nearly 70% of the public would be happy for their medical records to be shared between clinicians, a YouGov poll for The Times Health Commission has found. Its report, published this week, proposed patient record sharing through digital ‘patient passports’ and incentivising pharmacists ‘to do more prescribing, consultations and community care’ to relieve pressure on […] The post Seven in 10 back data sharing between clinicians appeared first on The Pharmacist.

Medical Records 118

Medical Records 118

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

STAT

FEBRUARY 8, 2024

A medical journal has retracted two studies claiming to show the harms of the abortion pill mifepristone, citing conflicts of interest by the authors and flaws in their research. Two of the three studies retracted by medical publisher Sage Perspectives were cited in a  pivotal Texas court ruling  that has threatened access to the pill. The  U.S.

339

339

pharmaphorum

FEBRUARY 8, 2024

Explore the commercial research landscape in the UK and the evolution of the National Institute for Health Research (NIHR) through an informative webinar.

124

124

pharmaphorum

FEBRUARY 8, 2024

Gilead Sciences has said it will no longer develop its CD47-targeting antibody magrolimab in blood cancers after data suggested that patients taking the drug in clinical trials were more likely to die than those in control groups.

111

111

STAT

FEBRUARY 8, 2024

A critical government advisory committee charged with charting U.S. vaccination policy appears to be atrophying, jeopardizing timely decision-making on how vaccines should be used in this country. The Advisory Committee on Immunization Practices, which has in recent years been a 15-person panel, has eight vacancies — one of which dates back more than a year.

Vaccines 318

Vaccines Immunity Immunization 318

BioPharma Dive

FEBRUARY 8, 2024

The German biotech will invest $200 million in Autolus — funds that, along with a $50 million fee, will give it licensing opportunities and access to supply infrastructure.

109

109

STAT

FEBRUARY 8, 2024

Three years ago, Jamie Lin, an early-career nephrologist at MD Anderson Cancer Center, made findings that could potentially help both save the kidneys of cancer patients and propel her career as a physician-scientist hoping to one day run her own lab. It was a promising start, but that’s when Lin says one of the Texas institute’s most powerful researchers interfered.

306

306

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management

Express Pharma

FEBRUARY 8, 2024

Biocon Biologics announced a five-year partnership with Sandoz AG which provides Sandoz the exclusive rights to promote, sell and distribute biosimilar Trastuzumab (market value of AUD $35 million) and biosimilar Bevacizumab (market value of AUD $45 million) in Australia. Under the agreement, Sandoz will distribute the Biocon Biologics’ brands, OGIVRI (bTrastuzumab) and ABEVMY (bBevacizumab), and facilitate the sustained access of these medications that were previously distributed by another pha

Biosimilars 103

Biosimilars Pharmaceutical Companies Pharmaceutical Companies 103

STAT

FEBRUARY 8, 2024

Has AI really solved biology? What can machines teach us about medicine? And what’s a digital twin? We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. It’s our all-AI episode. First, STAT’s Casey Ross joins us to explain his reporting on how researchers and pharmaceutical firms are using the technology to find new drug targets, design therapies, and improve clinical trials.

258

258

pharmaphorum

FEBRUARY 8, 2024

China has become the first country in the world to approve Roche’s anti-complement C5 antibody crovalimab, the only treatment for the rare disorder paroxysmal nocturnal haemoglobinuria (PNH) that can be given by subcutaneous injection.

100

100

STAT

FEBRUARY 8, 2024

This week, I address pushback I received on my Novartis-MorphoSys column. But first, a preview of the expected readout from Gritstone Bio’s neoantigen cancer vaccine study. A looming test for neoantigen cancer vaccines Before the end of the quarter, Gritstone Bio will release preliminary results from a randomized, Phase 2 clinical trial investigating a personalized therapeutic cancer vaccine in microsatellite-stable colon cancer, a type of “immunologically cold” tumor that i

Vaccines 256

Vaccines 256

Express Pharma

FEBRUARY 8, 2024

Deeptech startup Algorithmic Biologics (AlgoBio) launched the Tapestry platform for next-generation sequencing (NGS) at Genomics India Conference 2024 recently. The company informs that Tapestry empowers genomics labs to cut sequencing costs significantly by eliminating 60 to 90 per cent of library preparation costs that is 33-50 per cent of the total sequencing costs.

100

100

STAT

FEBRUARY 8, 2024

LONDON — Medicare’s first-ever drug pricing negotiations are officially underway. But neither government officials nor drugmakers are wanting to show their cards, at least publicly. Last week, Medicare made its first offers to the makers of the 10 products subject to negotiation, though it said it would be up to the companies to discuss the proposals.

Drug Pricing 247

Drug Pricing Diabetes 247

Express Pharma

FEBRUARY 8, 2024

Zydus Lifesciences has received final approvals from the United States Food and Drug Administration (USFDA) to manufacture and market Dexamethasone Tablets USP, 0.5 mg, 0.75 mg, 1.5 mg, 4 mg and 6 mg (USRLD: Decadron® Tablets) and Dexamethasone Tablets USP, 2 mg (USRLD: Dexamethasone Tablets). Dexamethasone is used to treat a number of different conditions, such as inflammation (swelling), severe allergies, adrenal problems, arthritis, asthma, blood or bone marrow problems, kidney problems, skin

99

99

STAT

FEBRUARY 8, 2024

You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine.  Sign up here  to receive it in your inbox on Tuesdays and Thursdays. A road test for fresh pharma CEOs A lot can change in five years — including the leadership of the three major pharmaceutical companies that will be testifying before Sen.

Pharmaceutical Companies 235

Pharmaceutical Companies Pharmaceutical Companies Drug Pricing Vaccines 235

Pharmaceutical Technology

FEBRUARY 8, 2024

AFFINITY data has spurred RegenxBio towards a pivotal study for DMD while pivotal CAMPSIITE data has the company moving towards an FDA BLA.

111

111

STAT

FEBRUARY 8, 2024

WASHINGTON — Call it Sen. Bernie Sanders’ prescription drug pricing theater. The hearing, featuring Merck CEO Robert Davis, Johnson and Johnson CEO Joaquin Duato, and Bristol Myers Squibb CEO Chris Boerner, was designed to draw public interest, and in that respect, it worked. The wood-paneled hearing room in a Senate office building was standing room only, with an overflow room prepared.

Drug Pricing 231

Drug Pricing 231

pharmaphorum

FEBRUARY 8, 2024

Stay up to date with the latest updates in the world of clinical trials. This week's highlights include Bayer's new study on aflibercept, BioNTech's groundbreaking research, and the exciting developments from Duality Bio. Get all the important information here.

92

92

STAT

FEBRUARY 8, 2024

By some measures, private equity investment lagged in 2023, a year marked by growing distress and high-profile downfalls among private equity-backed health care companies. Even so, three sectors still managed to see strong deal flow and prices: med spa, cardiology, and clinical trial sites, according to a new PitchBook report analyzing private equity investments in health care services in 2023.

Hospitals 220

Hospitals 220

Outsourcing Pharma

FEBRUARY 8, 2024

With independent pharmacies now facing significant challenges, healthcare SaaS provider Charac was pleased to announce more investment so it can accelerate a digitization drive.

Independent Pharmacies 105

Independent Pharmacies 105

STAT

FEBRUARY 8, 2024

Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. Good morning, everyone. Damian here with the latest Senate harangue for the drug industry, green shoots in biotech sentiment, and the potential of a gene therapy eye drop.

Drug Pricing 220

Drug Pricing Drug Development 220

European Pharmaceutical Review

FEBRUARY 8, 2024

Vertex Pharmaceuticals’ once-daily small molecule vanzacaftor/tezacaftor/deutivacaftor (vanza triple) for cystic fibrosis (CF) has gleaned positive results in Phase III trials. The Phase III trials The clinical programme for the once daily vanza triple was comprised of two Phase III trials: SKYLINE 102 and SKYLINE 103, evaluating the efficacy of vanzacaftor (20 mg)/tezacaftor (100 mg)/deutivacaftor (250 mg) in cystic fibrosis patients 12 years and older with at least one F508del mutation or a m

90

90

pharmaphorum

FEBRUARY 8, 2024

BioNTech has taken a $200 million stake in Autolus in a private placement that will allow it to tap into the UK company’s manufacturing capacity for CAR-T therapies

94

94

Pharma Times

FEBRUARY 8, 2024

The committee has advised that the vaccine should be given to those at the highest risk

Vaccines 121

Vaccines 121

pharmaphorum

FEBRUARY 8, 2024

Astellas appoints Nick Eshkenazi as chief digital and transformation officer (CTDO), the first time the pharma has included a digital role in its top management team

93

93

Express Pharma

FEBRUARY 8, 2024

Agilent India has been honoured with the Best Bioprocessing Supplier Award: Analytical Services at the Biopharma Excellence Awards (BEA) 2024. These prestigious awards, organized by IMAPAC, recognize organizations and technologies that contribute to vaccine research and development (R&D) and biologics manufacturing excellence in developing economies, particularly India.

Research Laboratories 90

Research Laboratories Vaccines 90

pharmaphorum

FEBRUARY 8, 2024

Autoimmune disease CAR-T therapy specialist Kyverna has upsized its IPO to $319m in another sign of an improving #biotech financing environment

101

101

Express Pharma

FEBRUARY 8, 2024

Pharma organisations are rethinking their approach to the setup and operations of their labs, with a focus on accelerating digitalisation, leveraging AI, improving processes, and building the right skills and culture for a lab transformation. The need to accelerate cycle times is driving change, with the majority (92 per cent) of pharma organisations listing this among the top drivers for future-ready ‘next-gen’ labs.

89

89

Outsourcing Pharma

FEBRUARY 8, 2024

Outsourcing Pharma and BioPharma Reporter breaks down the key people on the move in the pharma industry. Enhanc3D Genomics, Cytomos and Cellular Origins are among the companies welcoming new faces to top jobs.

105

105

The Pharmacist

FEBRUARY 8, 2024

Around 3,000 consultations were delivered through England’s new Pharmacy First service within its first three days, according to parliamentary under-secretary for health and social care Lord Markham. Speaking in the House of Lords on Tuesday, Lord Marham announced the figure and said that ‘clearly’ the new service ‘has been welcomed’. He added: ‘The early indications […] The post Pharmacy First delivers ‘around 3,000 consultations in first three days’ appeared first on The Pharmacist.

92

92

Pharmaceutical Technology

FEBRUARY 8, 2024

Despite several ground-breaking developments, pharmaceutical and biotech companies are often reluctant to invest in cell and gene therapy.

98

98

The Pharmacist

FEBRUARY 8, 2024

Former health secretary Dr Thérèse Coffey has praised Pharmacy First as a ‘sensible approach’ that treats pharmacists ‘like proper professionals’. In October 2022, as health secretary at the time, Dr Coffey faced backlash over claims that she was planning to allow pharmacists to prescribe antibiotics for certain conditions. This triggered concern from some healthcare professionals, […] The post Former health secretary praises ‘sensible approach’ of Pharmacy First appeared first on The Phar

89

89